{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-029524","form_type":"8-K","ticker":"ADCT","cik":"0001771910","company_name":"ADC Therapeutics SA","filed_at":"2026-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.884338+00:00","generated_at":"2026-05-14T23:57:26.466246+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ADC Therapeutics Q1 net product revenue $20.0M, net loss $0.21/share; cash runway into 2028","bullets":["Net product revenue $20.0M (up 15% YoY from $17.4M).","Net loss $33.0M ($0.21/share) vs $38.6M ($0.36/share) in Q1 2025; adjusted net loss $19.7M ($0.13/share).","Cash $231.0M as of Mar 31, 2026; cash runway at least into 2028.","LOTIS-5 Phase 3 topline results expected Q2 2026; full data and LOTIS-7 data by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-029524","json":"https://secwatch.observer/filing/0001628280-26-029524.json","markdown":"https://secwatch.observer/filing/0001628280-26-029524.md","text":"https://secwatch.observer/filing/0001628280-26-029524.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1771910/000162828026029524/0001628280-26-029524-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1771910/000162828026029524/adc-20260504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:57:26.466246+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9b53da2b938c8e270d36cb94082a84e41395ec97","claim":"ADC Therapeutics SA reported the first quarter ended March 31, 2026 results: revenue $20.0 million, net income $33.0 million, EPS $0.21 per basic and diluted share.","evidence_excerpt":"Updates LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year end First quarter 2026 net product revenue of $20.0 million Cash and cash equivalents of $231.0 million as of March 31, 2026, with an expected cash runway at least into 2028 Company to host conference call today at 8:30 a.m. EDT LAUSANNE,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1771910/000162828026029524/0001628280-26-029524-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Revenue","value":"$20.0 million"},{"label":"Net income","value":"$33.0 million"},{"label":"EPS","value":"$0.21 per basic and diluted share"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}